Results 161 to 170 of about 25,426 (206)

Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions. [PDF]

J Transl Med
Ghelli Luserna di Rorà A, Jandoubi M, Padella A, Ferrari A, Marranci A, Mazzotti C, Olimpico F, Ghetti M, Ledda L, Bochicchio MT, Paganelli M, Zanoni M, Cafaro A, Servili C, Galimberti S, Gottardi M, Rondoni M, Endri M, Onofrillo D, Audisio E, Marconi G, Simonetti G, Martinelli G.   +22 more
europepmc   +1 more source

R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts. [PDF]

Cancer Res
Liu ZS, Sinha S, Bannister M, Song A, Arriaga-Gomez E, McKeeken AJ, Bonner EA, Hanson BK, Sarchi M, Takashima K, Zong D, Corral VM, Nguyen E, Yoo J, Chiraphapphaiboon W, Leibson C, McMahon MC, Rai S, Swisher EM, Sachs Z, Chatla S, Stirewalt DL, Deeg HJ, Skorski T, Papapetrou EP, Walter MJ, Graubert TA, Doulatov S, Lee SC, Nguyen HD.   +29 more
europepmc   +1 more source

PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changes-Implications for UV-Induced DNA Repair and Photocarcinogenesis. [PDF]

Cancers (Basel), 2019
Hegedűs C, Boros G, Fidrus E, Kis GN, Antal M, Juhász T, Janka EA, Jankó L, Paragh G, Emri G, Bai P, Remenyik É.   +11 more
europepmc   +1 more source

PARP1 expression in breast cancer and effects of its inhibition in preclinical models

Breast cancer is the main cause of cancer death in women. Improved treatments, prevention programs and earlier detection are reducing the rate of death; however, there is still a high percentage of mortality by this cancer.
García Parra, Jetzabel
core  

PARP1 trapping activates ATM-mediated NF-κB signaling independent of replication in response to TOP1 blockade. [PDF]

Nucleic Acids Res
Bournique E, Sanchez A, Ha K, Yan KM, Manjunath L, Santiago G, Ortega P, Buisson R.   +7 more
europepmc   +1 more source

PARP1 as a novel therapeutic and diagnostic tool in autoimmune rheumatic diseases: a systematic literature review. [PDF]

Rheumatol Int
Dey M, Dey M.
europepmc   +1 more source

Structural Determinants of PARP1 Selectivity from Molecular Dynamics Analysis of PARP1 and PARP2 Complexes. [PDF]

Molecules
Shkil DO, Chesnokova NA, Ivashchenko AA, Petersen EV, Maximov PY.   +4 more
europepmc   +1 more source

Nucleophagy removes cytotoxic trapped PARP1. [PDF]

Nat Cell Biol
Hoslett G, Tribble S, Lascaux P, Koukouravas S, Torrecilla I, Song W, Hou CX, Li J, González-Fernández M, De Gregoriis G, Dagg RA, O'Brien D, Pierangelini A, Martial T, Ng AWT, Raimundo N, Milosevic I, Freire R, Li Y, Rottenberg S, Krastev DB, Lord CJ, Tarsounas M, Ramadan K.   +23 more
europepmc   +1 more source

PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications. [PDF]

Transl Oncol
Li J, Mu D, Li J, Lan M, Wu W, Zhang S, Dai Y.   +6 more
europepmc   +1 more source

In Vitro Evaluation of PARP1 Inhibitor Olaparib-Cyanine Dye Conjugate for the Treatment of Glioblastoma. [PDF]

ChemMedChem
Dumo C, Faheem, Choi PJ, Pederson NJ, Liu Y, Dragunow M, Park TI, Diehl KL, Jose J.   +8 more
europepmc   +1 more source